SWOG clinical trial number
S0518
Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Published
Abbreviated Title
CARCINOID Ph III depot octreotide + either interferon alpha or bevacizumab
Activated
12/01/2007
Closed
09/01/2012
Participants
Research committees
Gastrointestinal Cancer
Treatment
Interferon alpha-2b
Bevacizumab
Octreotide acetate for injectable suspension
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2303
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
CTSU/A022101
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
S2107
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
100% Accrual
Accrual
100%
Open
Phase